Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:35:34.425Z.
Calculation as of: 2026-10-06T13:35:34.425Z.
Quote observation: 2026-10-06T13:33:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f6ebf84f3f464cb4543e326b3b96959337d3a5891063dc6ef63f2f1a4491a7a3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.50M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.15M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artelo Biosciences, Inc. (ARTL) | $1.38M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.38M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | N/A | 8.14 | 8.14 | 8.14 |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.50M | N/A | 58.11 | 58.11 | 58.11 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.50M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.16M | N/A | 3.00 | 2.75 | 2.75 |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.15M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.09M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
